Cargando…

Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling

PURPOSE: To assess the dynamic link between continuous estrogen receptor (ER) expression and long-term clinical outcomes in non-metastatic breast cancer and to identify the ideal cutoff value for ER expression to optimize endocrine therapy use. METHODS: The study included 3055 female patients with s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Wenli, Fujii, Takeo, Ning, Jing, Iwase, Toshiaki, Qin, Jing, Ueno, Naoto T, Shen, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635323/ https://www.ncbi.nlm.nih.gov/pubmed/37961619 http://dx.doi.org/10.21203/rs.3.rs-3466989/v1

Ejemplares similares

Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
por: Fujii, Takeo, et al.
Publicado: (2017)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
por: Rody, Achim, et al.
Publicado: (2009)

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
por: Chen, Hai-long, et al.
Publicado: (2023)

Giant cell myocarditis in an older patient – reassessing the threshold for endomyocardial biopsy
por: Dusík, Milan, et al.
Publicado: (2020)

Reassessing the operative threshold for abdominal aortic aneurysm repair in the context of COVID-19
por: McGuinness, Brandon, et al.
Publicado: (2021)

Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis
por: Iovino, Francesco, et al.
Publicado: (2022)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Reassessment of Poststroke Dysphagia in Rehabilitation Facility Results in Reduction in Diet Restrictions
por: Pekacka-Egli, Anna Maria, et al.
Publicado: (2021)

Reassessing the Operative Threshold for Abdominal Aortic Aneurysm Repair in the Context of Coronavirus Disease 2019
por: McGuinness, Brandon, et al.
Publicado: (2020)

Follicular Size Threshold for Ovulation Reassessed. Insights from Multiple Ovulating Dairy Cows
por: López-Gatius, Fernando, et al.
Publicado: (2022)

Reassessing the Reassessment of suPAR in Glomerular Disease
por: Meijers, Björn K. I., et al.
Publicado: (2015)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping
por: Yu, Xinjian, et al.
Publicado: (2022)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
por: Cox, David G., et al.
Publicado: (2016)

RRAS2 shapes the TCR repertoire by setting the threshold for negative selection
por: Martínez-Riaño, Ana, et al.
Publicado: (2019)

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
por: Nederlof, I., et al.
Publicado: (2022)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer
por: Park, Chansub, et al.
Publicado: (2016)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER
por: Rajc, Jasmina, et al.
Publicado: (2018)

The 18-cm Thoracic-Height Threshold and Pulmonary Function in Non-Neuromuscular Early-Onset Scoliosis: A Reassessment
por: Johnston, Charles E., et al.
Publicado: (2021)

Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
por: Hecker, Michael, et al.
Publicado: (2011)

Over Restriction of Dietary Protein Allowance: The Importance of Ongoing Reassessment of Natural Protein Tolerance in Phenylketonuria
por: Pinto, Alex, et al.
Publicado: (2019)

Reassessment of contact restrictions and testing campaigns against COVID-19 via spatio-temporal modeling
por: Ganegoda, Naleen Chaminda, et al.
Publicado: (2021)

Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence
por: Czobor, Pál, et al.
Publicado: (2022)

Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study
por: Kwak, Youngji, et al.
Publicado: (2023)

Integrated multi‐omics profiling of high‐grade estrogen receptor‐positive, HER2‐negative breast cancer
por: Wang, Kang, et al.
Publicado: (2021)

Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy
por: Hu, Jianli, et al.
Publicado: (2021)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
por: Sun, Guang-Yi, et al.
Publicado: (2021)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
por: Yoder, Rachel, et al.
Publicado: (2022)

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
por: Fujii, Takeo, et al.
Publicado: (2017)

Reassessment of the threshold of the blood lead level to increase urinary δ‐aminolevulinic acid based on their relationship in recent lead workers in Japan
por: Ono, Akira, et al.
Publicado: (2021)

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
por: Lehmann-Che, Jacqueline, et al.
Publicado: (2013)

Expression of Autophagy-Related Proteins According to Androgen Receptor and HER-2 Status in Estrogen Receptor-Negative Breast Cancer
por: Kim, Ji-Ye, et al.
Publicado: (2014)

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
por: Hagio, Kanako, et al.
Publicado: (2021)

Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy
por: ÇAVDAR, Eyyüp, et al.
Publicado: (2022)

Reassessing blood acetylcholinesterase in dementia
por: Han, Pengcheng
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o62md2adrq4qrbf7v1cteh1o4m